Javascript doit fonctionner ! Activez-le et rechargez cette page.
Le Rézo de JeuxDeMots
• Types de relations
• Types de noeuds
• Consolider
le terme
  Options  
             

  Filtrage type relations : +   - (ex: 4, 12, 18, 36, 444, 555, 777)
  Filtrage valeur :          min   max
  Filtrage type noeuds :   +   - (ex: 4, 6, 8, 9, 10, 12, 18, 36, 444, 555, 777)

  Présentation de sortie :   (ex: -rien-, cloud, nicecloud)
 

'en:thalidomide-rituximab regimen'
(id=6899338 ; fe=en:thalidomide-rituximab regimen ; type=1 ; niveau=200 ; luminosité=25 ; somme entrante=1264 creation date=2017-06-25 touchdate=2025-04-26 17:46:05.000)
≈ 46 relations sortantes

  1. en:thalidomide-rituximab regimen -- r_associated #0: 39 / 1 -> en:pcr regimen
    n1=en:thalidomide-rituximab regimen | n2=en:pcr regimen | rel=r_associated | relid=0 | w=39
  2. en:thalidomide-rituximab regimen -- r_associated #0: 37 / 0.949 -> en:mine regimen
    n1=en:thalidomide-rituximab regimen | n2=en:mine regimen | rel=r_associated | relid=0 | w=37
  3. en:thalidomide-rituximab regimen -- r_associated #0: 36 / 0.923 -> en:epoch-o regimen
    n1=en:thalidomide-rituximab regimen | n2=en:epoch-o regimen | rel=r_associated | relid=0 | w=36
  4. en:thalidomide-rituximab regimen -- r_associated #0: 35 / 0.897 -> en:chop regimen
    n1=en:thalidomide-rituximab regimen | n2=en:chop regimen | rel=r_associated | relid=0 | w=35
  5. en:thalidomide-rituximab regimen -- r_associated #0: 35 / 0.897 -> en:cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine
    n1=en:thalidomide-rituximab regimen | n2=en:cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine | rel=r_associated | relid=0 | w=35
  6. en:thalidomide-rituximab regimen -- r_associated #0: 35 / 0.897 -> en:eshap regimen
    n1=en:thalidomide-rituximab regimen | n2=en:eshap regimen | rel=r_associated | relid=0 | w=35
  7. en:thalidomide-rituximab regimen -- r_associated #0: 35 / 0.897 -> en:macop-b regimen
    n1=en:thalidomide-rituximab regimen | n2=en:macop-b regimen | rel=r_associated | relid=0 | w=35
  8. en:thalidomide-rituximab regimen -- r_associated #0: 35 / 0.897 -> en:magrath regimen
    n1=en:thalidomide-rituximab regimen | n2=en:magrath regimen | rel=r_associated | relid=0 | w=35
  9. en:thalidomide-rituximab regimen -- r_associated #0: 35 / 0.897 -> en:r-ice regimen
    n1=en:thalidomide-rituximab regimen | n2=en:r-ice regimen | rel=r_associated | relid=0 | w=35
  10. en:thalidomide-rituximab regimen -- r_associated #0: 35 / 0.897 -> en:recurrent mantle cell lymphoma
    n1=en:thalidomide-rituximab regimen | n2=en:recurrent mantle cell lymphoma | rel=r_associated | relid=0 | w=35
  11. en:thalidomide-rituximab regimen -- r_associated #0: 34 / 0.872 -> en:codox-m/ivac regimen
    n1=en:thalidomide-rituximab regimen | n2=en:codox-m/ivac regimen | rel=r_associated | relid=0 | w=34
  12. en:thalidomide-rituximab regimen -- r_associated #0: 34 / 0.872 -> en:cyclophosphamide/prednisone/procarbazine/vincristine protocol
    n1=en:thalidomide-rituximab regimen | n2=en:cyclophosphamide/prednisone/procarbazine/vincristine protocol | rel=r_associated | relid=0 | w=34
  13. en:thalidomide-rituximab regimen -- r_associated #0: 34 / 0.872 -> en:hypercvad regimen
    n1=en:thalidomide-rituximab regimen | n2=en:hypercvad regimen | rel=r_associated | relid=0 | w=34
  14. en:thalidomide-rituximab regimen -- r_associated #0: 34 / 0.872 -> en:r-fm regimen
    n1=en:thalidomide-rituximab regimen | n2=en:r-fm regimen | rel=r_associated | relid=0 | w=34
  15. en:thalidomide-rituximab regimen -- r_associated #0: 34 / 0.872 -> en:refractory mantle cell lymphoma
    n1=en:thalidomide-rituximab regimen | n2=en:refractory mantle cell lymphoma | rel=r_associated | relid=0 | w=34
  16. en:thalidomide-rituximab regimen -- r_associated #0: 32 / 0.821 -> en:cnop regimen
    n1=en:thalidomide-rituximab regimen | n2=en:cnop regimen | rel=r_associated | relid=0 | w=32
  17. en:thalidomide-rituximab regimen -- r_associated #0: 32 / 0.821 -> en:dhap regimen
    n1=en:thalidomide-rituximab regimen | n2=en:dhap regimen | rel=r_associated | relid=0 | w=32
  18. en:thalidomide-rituximab regimen -- r_associated #0: 32 / 0.821 -> en:epoch protocol
    n1=en:thalidomide-rituximab regimen | n2=en:epoch protocol | rel=r_associated | relid=0 | w=32
  19. en:thalidomide-rituximab regimen -- r_associated #0: 32 / 0.821 -> en:f-machop regimen
    n1=en:thalidomide-rituximab regimen | n2=en:f-machop regimen | rel=r_associated | relid=0 | w=32
  20. en:thalidomide-rituximab regimen -- r_associated #0: 32 / 0.821 -> en:mini-beam regimen
    n1=en:thalidomide-rituximab regimen | n2=en:mini-beam regimen | rel=r_associated | relid=0 | w=32
  21. en:thalidomide-rituximab regimen -- r_associated #0: 31 / 0.795 -> en:platinol-fluororuracil regimen
    n1=en:thalidomide-rituximab regimen | n2=en:platinol-fluororuracil regimen | rel=r_associated | relid=0 | w=31
  22. en:thalidomide-rituximab regimen -- r_associated #0: 31 / 0.795 -> en:r-chop regimen
    n1=en:thalidomide-rituximab regimen | n2=en:r-chop regimen | rel=r_associated | relid=0 | w=31
  23. en:thalidomide-rituximab regimen -- r_associated #0: 31 / 0.795 -> en:r-cvp regimen
    n1=en:thalidomide-rituximab regimen | n2=en:r-cvp regimen | rel=r_associated | relid=0 | w=31
  24. en:thalidomide-rituximab regimen -- r_associated #0: 31 / 0.795 -> en:r-epoch regimen
    n1=en:thalidomide-rituximab regimen | n2=en:r-epoch regimen | rel=r_associated | relid=0 | w=31
  25. en:thalidomide-rituximab regimen -- r_associated #0: 31 / 0.795 -> en:r-fcm regimen
    n1=en:thalidomide-rituximab regimen | n2=en:r-fcm regimen | rel=r_associated | relid=0 | w=31
  26. en:thalidomide-rituximab regimen -- r_associated #0: 30 / 0.769 -> en:cde regimen
    n1=en:thalidomide-rituximab regimen | n2=en:cde regimen | rel=r_associated | relid=0 | w=30
  27. en:thalidomide-rituximab regimen -- r_associated #0: 30 / 0.769 -> en:fnd regimen
    n1=en:thalidomide-rituximab regimen | n2=en:fnd regimen | rel=r_associated | relid=0 | w=30
  28. en:thalidomide-rituximab regimen -- r_associated #0: 30 / 0.769 -> en:rituximab
    n1=en:thalidomide-rituximab regimen | n2=en:rituximab | rel=r_associated | relid=0 | w=30
  29. en:thalidomide-rituximab regimen -- r_associated #0: 29 / 0.744 -> en:hypercvad/hd mtx arac regimen
    n1=en:thalidomide-rituximab regimen | n2=en:hypercvad/hd mtx arac regimen | rel=r_associated | relid=0 | w=29
  30. en:thalidomide-rituximab regimen -- r_associated #0: 28 / 0.718 -> en:acvbp regimen
    n1=en:thalidomide-rituximab regimen | n2=en:acvbp regimen | rel=r_associated | relid=0 | w=28
  31. en:thalidomide-rituximab regimen -- r_associated #0: 28 / 0.718 -> en:calgb 9251 regimen
    n1=en:thalidomide-rituximab regimen | n2=en:calgb 9251 regimen | rel=r_associated | relid=0 | w=28
  32. en:thalidomide-rituximab regimen -- r_associated #0: 28 / 0.718 -> en:m-bacod regimen
    n1=en:thalidomide-rituximab regimen | n2=en:m-bacod regimen | rel=r_associated | relid=0 | w=28
  33. en:thalidomide-rituximab regimen -- r_associated #0: 28 / 0.718 -> en:m-bacop regimen
    n1=en:thalidomide-rituximab regimen | n2=en:m-bacop regimen | rel=r_associated | relid=0 | w=28
  34. en:thalidomide-rituximab regimen -- r_associated #0: 27 / 0.692 -> en:carboplatin/etoposide/ifosfamide
    n1=en:thalidomide-rituximab regimen | n2=en:carboplatin/etoposide/ifosfamide | rel=r_associated | relid=0 | w=27
  35. en:thalidomide-rituximab regimen -- r_associated #0: 27 / 0.692 -> en:chemotherapy regimen used to treat childhood non-hodgkin's lymphoma
    n1=en:thalidomide-rituximab regimen | n2=en:chemotherapy regimen used to treat childhood non-hodgkin's lymphoma | rel=r_associated | relid=0 | w=27
  36. en:thalidomide-rituximab regimen -- r_associated #0: 27 / 0.692 -> en:codox-m regimen
    n1=en:thalidomide-rituximab regimen | n2=en:codox-m regimen | rel=r_associated | relid=0 | w=27
  37. en:thalidomide-rituximab regimen -- r_associated #0: 27 / 0.692 -> en:rf regimen
    n1=en:thalidomide-rituximab regimen | n2=en:rf regimen | rel=r_associated | relid=0 | w=27
  38. en:thalidomide-rituximab regimen -- r_associated #0: 26 / 0.667 -> en:carboplatin/etoposide/melphalan regimen
    n1=en:thalidomide-rituximab regimen | n2=en:carboplatin/etoposide/melphalan regimen | rel=r_associated | relid=0 | w=26
  39. en:thalidomide-rituximab regimen -- r_associated #0: 26 / 0.667 -> en:cyclophosphamide/prednisone/vincristine protocol
    n1=en:thalidomide-rituximab regimen | n2=en:cyclophosphamide/prednisone/vincristine protocol | rel=r_associated | relid=0 | w=26
  40. en:thalidomide-rituximab regimen -- r_associated #0: 26 / 0.667 -> en:promace-cytabom regimen
    n1=en:thalidomide-rituximab regimen | n2=en:promace-cytabom regimen | rel=r_associated | relid=0 | w=26
  41. en:thalidomide-rituximab regimen -- r_associated #0: 26 / 0.667 -> en:thalidomide
    n1=en:thalidomide-rituximab regimen | n2=en:thalidomide | rel=r_associated | relid=0 | w=26
  42. en:thalidomide-rituximab regimen -- r_associated #0: 20 / 0.513 -> en:chope regimen
    n1=en:thalidomide-rituximab regimen | n2=en:chope regimen | rel=r_associated | relid=0 | w=20
  43. en:thalidomide-rituximab regimen -- r_associated #0: 20 / 0.513 -> en:copp regimen
    n1=en:thalidomide-rituximab regimen | n2=en:copp regimen | rel=r_associated | relid=0 | w=20
  44. en:thalidomide-rituximab regimen -- r_associated #0: 20 / 0.513 -> en:fc regimen
    n1=en:thalidomide-rituximab regimen | n2=en:fc regimen | rel=r_associated | relid=0 | w=20
  45. en:thalidomide-rituximab regimen -- r_associated #0: 20 / 0.513 -> rituximab
    n1=en:thalidomide-rituximab regimen | n2=rituximab | rel=r_associated | relid=0 | w=20
  46. en:thalidomide-rituximab regimen -- r_associated #0: 2 / 0.051 -> en:therapeutic or preventive procedure
    n1=en:thalidomide-rituximab regimen | n2=en:therapeutic or preventive procedure | rel=r_associated | relid=0 | w=2
≈ 47 relations entrantes

  1. rituximab --- r_associated #0: 65 --> en:thalidomide-rituximab regimen
    n1=rituximab | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=65
  2. en:rituximab --- r_associated #0: 64 --> en:thalidomide-rituximab regimen
    n1=en:rituximab | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=64
  3. en:dhap regimen --- r_associated #0: 43 --> en:thalidomide-rituximab regimen
    n1=en:dhap regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=43
  4. en:carboplatin/etoposide/melphalan regimen --- r_associated #0: 35 --> en:thalidomide-rituximab regimen
    n1=en:carboplatin/etoposide/melphalan regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=35
  5. en:mine regimen --- r_associated #0: 35 --> en:thalidomide-rituximab regimen
    n1=en:mine regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=35
  6. en:codox-m/ivac regimen --- r_associated #0: 34 --> en:thalidomide-rituximab regimen
    n1=en:codox-m/ivac regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=34
  7. en:macop-b regimen --- r_associated #0: 34 --> en:thalidomide-rituximab regimen
    n1=en:macop-b regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=34
  8. en:r-fm regimen --- r_associated #0: 34 --> en:thalidomide-rituximab regimen
    n1=en:r-fm regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=34
  9. en:cnop regimen --- r_associated #0: 32 --> en:thalidomide-rituximab regimen
    n1=en:cnop regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=32
  10. en:magrath regimen --- r_associated #0: 32 --> en:thalidomide-rituximab regimen
    n1=en:magrath regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=32
  11. en:chope regimen --- r_associated #0: 30 --> en:thalidomide-rituximab regimen
    n1=en:chope regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=30
  12. en:copp regimen --- r_associated #0: 30 --> en:thalidomide-rituximab regimen
    n1=en:copp regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=30
  13. en:epoch-o regimen --- r_associated #0: 30 --> en:thalidomide-rituximab regimen
    n1=en:epoch-o regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=30
  14. en:fc regimen --- r_associated #0: 30 --> en:thalidomide-rituximab regimen
    n1=en:fc regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=30
  15. en:hypercvad/hd mtx arac regimen --- r_associated #0: 30 --> en:thalidomide-rituximab regimen
    n1=en:hypercvad/hd mtx arac regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=30
  16. en:mini-beam regimen --- r_associated #0: 30 --> en:thalidomide-rituximab regimen
    n1=en:mini-beam regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=30
  17. en:pcr regimen --- r_associated #0: 29 --> en:thalidomide-rituximab regimen
    n1=en:pcr regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=29
  18. en:rf regimen --- r_associated #0: 29 --> en:thalidomide-rituximab regimen
    n1=en:rf regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=29
  19. en:chemotherapy regimen used to treat childhood non-hodgkin's lymphoma --- r_associated #0: 28 --> en:thalidomide-rituximab regimen
    n1=en:chemotherapy regimen used to treat childhood non-hodgkin's lymphoma | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=28
  20. en:codox-m regimen --- r_associated #0: 28 --> en:thalidomide-rituximab regimen
    n1=en:codox-m regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=28
  21. en:m-bacod regimen --- r_associated #0: 28 --> en:thalidomide-rituximab regimen
    n1=en:m-bacod regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=28
  22. en:promace-cytabom regimen --- r_associated #0: 28 --> en:thalidomide-rituximab regimen
    n1=en:promace-cytabom regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=28
  23. en:r-fcm regimen --- r_associated #0: 28 --> en:thalidomide-rituximab regimen
    n1=en:r-fcm regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=28
  24. en:eshap regimen --- r_associated #0: 27 --> en:thalidomide-rituximab regimen
    n1=en:eshap regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=27
  25. en:fnd regimen --- r_associated #0: 27 --> en:thalidomide-rituximab regimen
    n1=en:fnd regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=27
  26. en:acvbp regimen --- r_associated #0: 26 --> en:thalidomide-rituximab regimen
    n1=en:acvbp regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=26
  27. en:platinol-fluororuracil regimen --- r_associated #0: 21 --> en:thalidomide-rituximab regimen
    n1=en:platinol-fluororuracil regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=21
  28. en:calgb 9251 regimen --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:calgb 9251 regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  29. en:carboplatin/etoposide/ifosfamide --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:carboplatin/etoposide/ifosfamide | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  30. en:cde regimen --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:cde regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  31. en:chop regimen --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:chop regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  32. en:cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  33. en:cyclophosphamide/prednisone/procarbazine/vincristine protocol --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:cyclophosphamide/prednisone/procarbazine/vincristine protocol | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  34. en:cyclophosphamide/prednisone/vincristine protocol --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:cyclophosphamide/prednisone/vincristine protocol | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  35. en:epoch protocol --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:epoch protocol | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  36. en:f-machop regimen --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:f-machop regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  37. en:hypercvad regimen --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:hypercvad regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  38. en:m-bacop regimen --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:m-bacop regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  39. en:r-chop regimen --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:r-chop regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  40. en:r-cvp regimen --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:r-cvp regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  41. en:r-epoch regimen --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:r-epoch regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  42. en:r-ice regimen --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:r-ice regimen | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  43. en:recurrent mantle cell lymphoma --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:recurrent mantle cell lymphoma | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  44. en:refractory mantle cell lymphoma --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:refractory mantle cell lymphoma | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  45. en:thalidomide --- r_associated #0: 20 --> en:thalidomide-rituximab regimen
    n1=en:thalidomide | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=20
  46. Ritter-Lyell (syndrome de) --- r_associated #0: 10 --> en:thalidomide-rituximab regimen
    n1=Ritter-Lyell (syndrome de) | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=10
  47. Rituximab --- r_associated #0: 5 --> en:thalidomide-rituximab regimen
    n1=Rituximab | n2=en:thalidomide-rituximab regimen | rel=r_associated | relid=0 | w=5
Le service Rézo permet d'énumérer les relations existant pour un terme. Ce service est interrogeable par programme.
Projet JeuxDeMots - url: http://www.jeuxdemots.org
contact: mathieu.lafourcade@lirmm.fr